Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: Phys Med Biol. 2012 Oct 10;57(21):7117–7132. doi: 10.1088/0031-9155/57/21/7117

Figure 5.

Figure 5

Predicted RRR of second cancer in the bladder and rectum following prostate radiotherapy for VMAT and proton arc therapy for the small, medium, and large patients for the linear-non-threshold (LNT), linear-exponential-10 (Lexp 10), linear-exponential-40 (Lexp 40), linear-plateau-10 (Lplat 10), and linear-plateau-40 (Lplat 40) risk models. The mean RRR is listed above each group, where a and b represent a statistically significant advantage for proton arc therapy (p-value < 0.05) with respect to risk calculated with the Student's t-test and exact sign test, respectively.